Ensign Peak Advisors’s Denali Therapeutics DNLI Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $6.63M | Sell |
473,695
-114,090
| -19% | -$1.6M | 0.01% | 579 |
|
|
2025
Q1 | $7.99M | Buy |
587,785
+241,481
| +70% | +$3.28M | 0.02% | 521 |
|
|
2024
Q4 | $7.06M | Hold |
346,304
| – | – | 0.01% | 559 |
|
|
2024
Q3 | $10.1M | Hold |
346,304
| – | – | 0.02% | 467 |
|
|
2024
Q2 | $8.04M | Hold |
346,304
| – | – | 0.01% | 508 |
|
|
2024
Q1 | $7.11M | Sell |
346,304
-2,193
| -0.6% | -$45K | 0.01% | 537 |
|
|
2023
Q4 | $7.48M | Hold |
348,497
| – | – | 0.01% | 519 |
|
|
2023
Q3 | $7.19M | Buy |
348,497
+200,000
| +135% | +$4.13M | 0.02% | 475 |
|
|
2023
Q2 | $4.38M | Buy |
148,497
+3,950
| +3% | +$117K | 0.01% | 622 |
|
|
2023
Q1 | $3.33M | Buy |
144,547
+2,000
| +1% | +$46.1K | 0.01% | 676 |
|
|
2022
Q4 | $3.96M | Buy |
142,547
+19,900
| +16% | +$553K | 0.01% | 612 |
|
|
2022
Q3 | $3.76M | Buy |
122,647
+36,975
| +43% | +$1.13M | 0.01% | 595 |
|
|
2022
Q2 | $2.52M | Sell |
85,672
-18,904
| -18% | -$556K | 0.01% | 718 |
|
|
2022
Q1 | $3.37M | Buy |
104,576
+120
| +0.1% | +$3.86K | 0.01% | 701 |
|
|
2021
Q4 | $4.66M | Buy |
104,456
+38,108
| +57% | +$1.7M | 0.01% | 684 |
|
|
2021
Q3 | $3.35M | Buy |
66,348
+24,406
| +58% | +$1.23M | 0.01% | 825 |
|
|
2021
Q2 | $3.29M | Buy |
41,942
+300
| +0.7% | +$23.5K | 0.01% | 833 |
|
|
2021
Q1 | $2.38M | Sell |
41,642
-16,280
| -28% | -$930K | 0.01% | 1021 |
|
|
2020
Q4 | $4.85M | Buy |
57,922
+201
| +0.3% | +$16.8K | 0.01% | 619 |
|
|
2020
Q3 | $2.07M | Buy |
57,721
+414
| +0.7% | +$14.8K | 0.01% | 955 |
|
|
2020
Q2 | $1.39M | Sell |
57,307
-67,842
| -54% | -$1.64M | ﹤0.01% | 1153 |
|
|
2020
Q1 | $2.19M | Buy |
125,149
+117,173
| +1,469% | +$2.05M | 0.01% | 791 |
|
|
2019
Q4 | $139K | Buy |
+7,976
| New | +$139K | ﹤0.01% | 1635 |
|